Ident. | Authors (with country if any) | Title |
---|
000127 |
Hasmet A. Hanagasi [Turquie] ; Hakan Gurvit [Turquie] ; P Nar Unsalan [Turquie] ; Hilal Horozoglu [Turquie] ; Nese Tuncer [Turquie] ; Aynur Feyzioglu [Turquie] ; Dilek Ince Gunal [Turquie] ; Gorsev G. Yener [Turquie] ; Raif Cakmur [Turquie] ; Huseyin A. Sahin [Turquie] ; Murat Emre [Turquie] | The effects of rasagiline on cognitive deficits in Parkinson's disease patients without dementia: A randomized, double‐blind, placebo‐controlled, multicenter study |
000318 |
Peter Jenner [Royaume-Uni] ; J. William Langston [États-Unis] | Explaining ADAGIO: A critical review of the biological basis for the clinical effects of rasagiline |
000328 |
F. Stocchi [Italie] ; J. M. Rabey [Israël] | Effect of rasagiline as adjunct therapy to levodopa on severity of OFF in Parkinson’s disease |
000733 |
H. Reichmann ; W. H. Jost [Allemagne] | Efficacy and tolerability of rasagiline in daily clinical use – a post‐marketing observational study in patients with Parkinson’s disease |
000915 |
Nir Giladi [Israël] ; Joseph Tal [Israël] ; Tali Azulay [Israël] ; Olivier Rascol [France] ; David J. Brooks [Royaume-Uni] ; Eldad Melamed [Israël] ; Wolfgang Oertel [Allemagne] ; Werner Poewe [Autriche] ; Fabrizio Stocchi [Italie] ; Eduardo Tolosa [Espagne] | Validation of the freezing of gait questionnaire in patients with Parkinson's disease |
000A43 |
Robert A. Hauser [États-Unis] ; Mark F. Lew [États-Unis] ; Howard I. Hurtig [États-Unis] ; William G. Ondo [États-Unis] ; Joanne Wojcieszek [États-Unis] ; Cheryl J. Fitzer-Attas [Israël] | Long‐term outcome of early versus delayed rasagiline treatment in early Parkinson's disease |
000E78 |
C. Warren Olanow [États-Unis] ; Robert A. Hauser [États-Unis] ; Joseph Jankovic [États-Unis] ; William Langston [États-Unis] ; Anthony Lang [Canada] ; Werner Poewe [Autriche] ; Eduardo Tolosa [Espagne] ; Fabrizio Stocchi [Italie] ; Eldad Melamed [Israël] ; Eli Eyal [Israël] ; Olivier Rascol [France] | A randomized, double‐blind, placebo‐controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): Rationale, design, and baseline characteristics |
001008 |
Fernandez [États-Unis] ; Chen [États-Unis] | Monoamine Oxidase‐B Inhibition in the Treatment of Parkinson's Disease |
001311 |
J. Antonelle Demarcaida [États-Unis] ; Steven R. Schwid [États-Unis] ; William B. White [États-Unis] ; Karen Blindauer [États-Unis] ; Stanley Fahn [États-Unis] ; Karl Kieburtz [États-Unis] ; Matthew Stern [États-Unis] ; Ira Shoulson [États-Unis] | Effects of tyramine administration in Parkinson's disease patients treated with selective MAO‐B inhibitor rasagiline |
001436 |
Moussa B. H. Youdim [Israël] ; Orit Bar Am [Israël] ; Merav Yogev-Falach [Israël] ; Orly Weinreb [Israël] ; Wakako Maruyama [Japon] ; Makato Naoi [Japon] ; Tamar Amit [Israël] | Rasagiline: Neurodegeneration, neuroprotection, and mitochondrial permeability transition |
001453 |
Orly Weinreb [Israël] ; Tamar Amit [Israël] ; Orit Bar-Am [Israël] ; Orly Chillag-Talmor [Israël] ; Moussa B. H. Youdim [Israël] | Novel Neuroprotective Mechanism of Action of Rasagiline Is Associated with Its Propargyl Moiety: Interaction of Bcl‐2 Family Members with PKC Pathway |
001523 |
Chen [États-Unis] ; Swope [États-Unis] | Clinical Pharmacology of Rasagiline: A Novel, Second‐Generation Propargylamine for the Treatment of Parkinson Disease |
001648 |
Matthew B. Stern [États-Unis] ; Kenneth L. Marek [États-Unis] ; Joseph Friedman [États-Unis] ; Robert A. Hauser [États-Unis] ; Peter A. Lewitt [États-Unis] ; Daniel Tarsy [États-Unis] ; C. Warren Olanow [États-Unis] | Double‐blind, randomized, controlled trial of rasagiline as monotherapy in early Parkinson's disease patients |